ArticleFrontiers in oncology2021
Unraveling Heterogeneity of Tumor Cells and Microenvironment and Its Clinical Implications for Triple Negative Breast Cancer.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Spatial and temporal intratumoral heterogeneity in breast cancer: a systematic and conceptual review of single-cell and spatial omics studies.BMC cancer · 2026Pooled it
- CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts Anti-PD-1 Efficacy in Transgenic Mammary Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Structure-Function Regulation of Proteolytically Stable Amphiphilic Peptide-Based Soft Materials With Antimicrobial Efficacy Against Drug-Resistant Strains and Anticancer Activity in Triple-Negative Breast Cancer Cells.Chembiochem : a European journal of chemical biology · 2026Article
- Prognostic and therapeutic implications of PSMD14 in hepatocellular carcinoma: an integrative analysis of transcriptomic and single-cell profiles.Translational cancer research · 2026Article
- CXCR2-Dependent Infiltration of Tumor-Associated Neutrophils Is Linked to Enhanced CD8International journal of molecular sciences · 2026Article
- Integrative Raman Spectroscopy and Multi-Omics Analysis of Lipid and Matrix Protein Heterogeneity in Triple-Negative Breast Cancer.Chemical & biomedical imaging · 2026Article
- Differential Expression of Epstein-Barr Virus Sequences in Various Breast Cancer Subtypes.Genes · 2025Article
- Computational identification of surface markers for isolating distinct subpopulations from heterogeneous cancer cell populations.NPJ systems biology and applications · 2024Article
- Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer.ESMO real world data and digital oncology · 2024Article
- Article
- Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance.Genes & diseases · 2024Review
- Cell Cycle Status Influences Resistance to Apoptosis Induced by Oxidative Stress in Human Breast Cancer Cells, Which Is Accompanied by Modulation of Autophagy.Current issues in molecular biology · 2023Article
- Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance.Breast cancer research : BCR · 2023Review
- Expression and prognostic signatures of m6A-related lncRNAs in hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2023Article
- SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.International journal of cancer · 2023Article
- Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer.International journal of molecular sciences · 2023Article
- Breast cancer heterogeneity and its implication in personalized precision therapy.Experimental hematology & oncology · 2023Review
- Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse.Frontiers in immunology · 2023Article
- Phenotypic heterogeneity drives differential disease outcome in a mouse model of triple negative breast cancer.Frontiers in oncology · 2023Article
- Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (-) Breast Cancer.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.